Bedaquiline + Pretomanid + Linezolid + Moxifloxacin (BPaLM Regimen)
Treatment for Hiv Aids Extensively Drug Resistant Tuberculosis
Typical Dosage: Bedaquiline: 400mg daily (2 weeks), then 200mg 3x/week (22 weeks); Pretomanid: 200mg daily; Linezolid: 600mg daily (often reduced to 300mg); Moxifloxacin: 400mg daily
Effectiveness
89%
Safety Score
36%
Clinical Trials
15
Participants
1.5K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
36
DangerousModerateSafe
Treatment Details
Dosage Range
Bedaquiline: 400mg daily (2 weeks), then 200mg 3x/week (22 weeks); Pretomanid: 200mg daily; Linezolid: 600mg daily (often reduced to 300mg); Moxifloxacin: 400mg daily
Time to Effect
2-4 weeks (sputum conversion), 1-2 months (clinical improvement)
Treatment Duration
6-9 months
Evidence Quality
HIGHNumber Needed to Treat (NNT)
2(Treat 2 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
7(Treat 7 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$41,000
Monitoring:$4,000
Side Effect Mgmt:$6,000
Total Annual:$51,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$6,375/QALY
QALYs Gained
8
Outcome-Based Costs
Cost per Responder
$57,303
Cost per Remission
$57,303
Comparison vs Longer-course XDR-TB regimen (e.g., individualized regimen with injectables, up to 24 months)
Cost Difference
$-5,000/year
Less expensive
QALY Difference
+2.00 QALYs
Better outcomes
Dominance
DOMINATESBetter + cheaper
Bedaquiline + Pretomanid + Linezolid + Moxifloxacin (BPaLM Regimen) Outcomes
for Hiv Aids Extensively Drug Resistant Tuberculosis
Efficacy Outcomes
Overall Effectiveness
+89%
Response Rate
+89%
Remission Rate
+89%
Common Side Effects
Peripheral neuropathy
+60%
Myelosuppression (anemia, thrombocytopenia)
+25%
Hepatotoxicity
+20%
QT prolongation
+20%
Optic neuropathy
+7%
Gastrointestinal disturbances
+15%
Tendonitis/rupture
+5%
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov